Nucleus Software Exports Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
November 09, 2023 at 03:47 am EST
Share
Nucleus Software Exports Limited reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported revenue was INR 2,171.1 million compared to INR 1,388.9 million a year ago. Net income was INR 445.9 million compared to INR 110.3 million a year ago. Basic earnings per share from continuing operations was INR 16.65 compared to INR 4.12 a year ago. Diluted earnings per share from continuing operations was INR 16.65 compared to INR 4.12 a year ago.
For the six months, revenue was INR 4,367.5 million compared to INR 2,739.4 million a year ago. Net income was INR 981.5 million compared to INR 218 million a year ago. Basic earnings per share from continuing operations was INR 36.66 compared to INR 8.14 a year ago. Diluted earnings per share from continuing operations was INR 36.66 compared to INR 8.14 a year ago.
Nucleus Software Exports Limited is a provider of lending and transaction banking products to the financial services industry. The Company is engaged in the business of development and marketing of software, product, and software services for business entities in the banking and financial services (BFS) vertical having its operating units located in Noida, Uttar Pradesh. It operates in seven geographical segments: India, Far East, Southeast Asia, Europe, Middle East, Africa, and Australia. Its two flagship products include FinnOne Neo and FinnAxia. FinnOne Neo suite is an end-to-end solution for lending businesses. FinnAxia suite offers an enterprise solution for the transaction banking operations of corporate banks. It provides various lending, such as FinnOne Neo retail lending, FinnOne Neo corporate lending, FinnOne Neo digital channels, and Nucleus lending analytics. Its transaction banking includes advisory services and FinnAxia cash and liquidity management.
NUCLEUS SOFTWARE EXPORTS LIMITED 
